O-glcnacylation treatment for ischemic brain injury
US2014357572A1
Neurotrophic peptides for the treatment of tauopathies
US2015252087A1
Treatment of brain injury with a neurotrophic peptide
US2013157946A1
Neurotrophic peptides
US2013143809A1
Neurotrophic peptides
US2010273196A1
Method for evaluating blood-neural barrier permeability
WO2008070296A2
System and method for diagnosis and treatment of neuropsychiatric disorders
US2008070263A1
Method for Differentiation of Alzheimer's Disease into Subgroups
WO2005018424A2
Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
US2006014209A1
Method for differentiation of Alzheimer's Disease into subgroups
WO2005021711A2
Approach for obtaining monoclonal antibodies to cell surface proteins
US2007105105A1
Surrogate cell gene expression signatures for evaluating the physical state of a subject
US7161060B1
Transgenic mice comprising a genomic human tau transgene
AU4731701A
A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer
US5958785A
Detection of a carbohydrate biomarker directly associated with chronic alcoholism
US5602150A
Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
AU1831195A
Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
US5747346A
Detection of novel carbohydrates directly associated with chronic alcoholism
US5589741A
System for creating naturalistic illumination cycles
